202 related articles for article (PubMed ID: 37240301)
1. Hypoxia Is Associated with Increased Immune Infiltrates and Both Anti-Tumour and Immune Suppressive Signalling in Muscle-Invasive Bladder Cancer.
Smith V; Lee D; Reardon M; Shabbir R; Sahoo S; Hoskin P; Choudhury A; Illidge T; West CML
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240301
[TBL] [Abstract][Full Text] [Related]
2. The effect of hypoxia on PD-L1 expression in bladder cancer.
Smith V; Mukherjee D; Lunj S; Choudhury A; Hoskin P; West C; Illidge T
BMC Cancer; 2021 Nov; 21(1):1271. PubMed ID: 34819027
[TBL] [Abstract][Full Text] [Related]
3. Enhanceosomes as integrators of hypoxia inducible factor (HIF) and other transcription factors in the hypoxic transcriptional response.
Pawlus MR; Hu CJ
Cell Signal; 2013 Sep; 25(9):1895-903. PubMed ID: 23707522
[TBL] [Abstract][Full Text] [Related]
4. Fibronectin-1: A Predictive Immunotherapy Response Biomarker for Muscle‑Invasive Bladder Cancer.
Zhang X; Liu H; Zhang J; Wang Z; Yang S; Liu D; Liu J; Li Y; Fu X; Zhang X
Arch Esp Urol; 2023 Feb; 76(1):70-83. PubMed ID: 36914422
[TBL] [Abstract][Full Text] [Related]
5. STAT3 or USF2 contributes to HIF target gene specificity.
Pawlus MR; Wang L; Murakami A; Dai G; Hu CJ
PLoS One; 2013; 8(8):e72358. PubMed ID: 23991099
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment.
Kumar V; Gabrilovich DI
Immunology; 2014 Dec; 143(4):512-9. PubMed ID: 25196648
[TBL] [Abstract][Full Text] [Related]
7. TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.
Liu Z; Zeng H; Jin K; Yu Y; You R; Zhang H; Liu C; Su X; Yan S; Chang Y; Liu L; Xu L; Xu J; Zhu Y; Wang Z
Br J Cancer; 2022 May; 126(9):1310-1317. PubMed ID: 35039625
[TBL] [Abstract][Full Text] [Related]
8. Tumour microenvironment (TME) characterization identified prognosis and immunotherapy response in muscle-invasive bladder cancer (MIBC).
Cao R; Yuan L; Ma B; Wang G; Tian Y
Cancer Immunol Immunother; 2021 Jan; 70(1):1-18. PubMed ID: 32617668
[TBL] [Abstract][Full Text] [Related]
9. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival.
Giatromanolaki A; Koukourakis MI; Sivridis E; Turley H; Talks K; Pezzella F; Gatter KC; Harris AL
Br J Cancer; 2001 Sep; 85(6):881-90. PubMed ID: 11556841
[TBL] [Abstract][Full Text] [Related]
10. Identification of the hypoxia-inducible factor 2α nuclear interactome in melanoma cells reveals master proteins involved in melanoma development.
Steunou AL; Ducoux-Petit M; Lazar I; Monsarrat B; Erard M; Muller C; Clottes E; Burlet-Schiltz O; Nieto L
Mol Cell Proteomics; 2013 Mar; 12(3):736-48. PubMed ID: 23275444
[TBL] [Abstract][Full Text] [Related]
11. Drug resistance and cancer stem cells: the shared but distinct roles of hypoxia-inducible factors HIF1α and HIF2α.
Schöning JP; Monteiro M; Gu W
Clin Exp Pharmacol Physiol; 2017 Feb; 44(2):153-161. PubMed ID: 27809360
[TBL] [Abstract][Full Text] [Related]
12. Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
Li W; Liu Z; Jin K; Shao F; Zeng H; Wang Y; Zhu Y; Xu L; Wang Z; Chang Y; Zhang W
BMC Cancer; 2023 Jul; 23(1):661. PubMed ID: 37452272
[TBL] [Abstract][Full Text] [Related]
13. Poor clinical outcomes and immunoevasive contexture in SIRPα
Xu Z; Zeng H; Liu Z; Jin K; Chang Y; Wang Y; Liu L; Zhu Y; Xu L; Wang Z; Guo J; Xu J
Urol Oncol; 2022 Mar; 40(3):109.e11-109.e20. PubMed ID: 34600802
[TBL] [Abstract][Full Text] [Related]
14. A TP53-based immune prognostic model for muscle-invasive bladder cancer.
Li H; Lu H; Cui W; Huang Y; Jin X
Aging (Albany NY); 2020 Dec; 13(2):1929-1946. PubMed ID: 33323544
[TBL] [Abstract][Full Text] [Related]
15. Upstream stimulatory factor 2 and hypoxia-inducible factor 2α (HIF2α) cooperatively activate HIF2 target genes during hypoxia.
Pawlus MR; Wang L; Ware K; Hu CJ
Mol Cell Biol; 2012 Nov; 32(22):4595-610. PubMed ID: 22966206
[TBL] [Abstract][Full Text] [Related]
16. Construction of an Immune-Associated Gene-Based Signature in Muscle-Invasive Bladder Cancer.
Shen C; Xu T; Sun Y; Wang L; Liang Z; Niu H; Jiao W; Wang Y
Dis Markers; 2020; 2020():8866730. PubMed ID: 33456631
[TBL] [Abstract][Full Text] [Related]
17. The HIF1α/HIF2α-miR210-3p network regulates glioblastoma cell proliferation, dedifferentiation and chemoresistance through EGF under hypoxic conditions.
Wang P; Yan Q; Liao B; Zhao L; Xiong S; Wang J; Zou D; Pan J; Wu L; Deng Y; Wu N; Gong S
Cell Death Dis; 2020 Nov; 11(11):992. PubMed ID: 33208727
[TBL] [Abstract][Full Text] [Related]
18. Molecular, Immunological, and Clinical Features Associated With Lymphoid Neogenesis in Muscle Invasive Bladder Cancer.
Pagliarulo F; Cheng PF; Brugger L; van Dijk N; van den Heijden M; Levesque MP; Silina K; van den Broek M
Front Immunol; 2021; 12():793992. PubMed ID: 35145509
[TBL] [Abstract][Full Text] [Related]
19. Tumor-associated macrophages and Tregs influence and represent immune cell infiltration of muscle-invasive bladder cancer and predict prognosis.
Koll FJ; Banek S; Kluth L; Köllermann J; Bankov K; Chun FK; Wild PJ; Weigert A; Reis H
J Transl Med; 2023 Feb; 21(1):124. PubMed ID: 36793050
[TBL] [Abstract][Full Text] [Related]
20. Enhanced HIF2α expression during human trophoblast differentiation into syncytiotrophoblast suppresses transcription of placental growth factor.
Fujii T; Nagamatsu T; Morita K; Schust DJ; Iriyama T; Komatsu A; Osuga Y; Fujii T
Sci Rep; 2017 Sep; 7(1):12455. PubMed ID: 28963486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
